FY15-14: Tularemia Vaccine Protocol (NDBR Lot 4)

首次发布于 2019 年 3 月 7 日

Safety and Immunogenicity Study of a Live Francisella Tularensis Vaccine

计划入组 484 人 · 首次发布于 2008 年 1 月 2 日

Continued Safety and Immunogenicity Study of a Live Francisella Tularensis Vaccine

计划入组 1,000 人 · 首次发布于 2008 年 11 月 10 日

Live attenuated tularemia vaccine (U.S. Army Medical Research and Materiel Command)

Tularemia vaccine(DynPort Vaccine Co. LLC)

inactivated bacterial vector vaccine (Cerus)

Three Probable Tularemia Cases Reported in Suffolk County, Raising Tick-Borne Disease Concerns

Appili Therapeutics Advances Pipeline with FDA-Approved Drug Launch and Vaccine Progress

Appili Therapeutics Secures $40 Million NIAID Contract for Antifungal Vaccine Development